12:00 AM
Feb 27, 2012
 |  BC Week In Review  |  Company News  |  Other News

Active Biotech cancer, autoimmune news

Active Biotech said in its 2011 financial statement that it plans to reduce headcount by up to 25 (32%) to about 55 following a comprehensive overview of the organization. The company said its partners will increasingly handle projects as they move along in development. The company will focus on the Phase III trial of tasquinimod ( TASQ) to treat metastatic castration-resistant prostate cancer (CRPC), as well as the...

Read the full 321 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >